Recruiting

Observational Study

Sponsor:

Texas A&M University

Code:

NCT06726590

Conditions

Diabetes

Cholesterol

Cancer

Blood Pressure Disorders

Heart Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This program collects genetic and health information to help doctors choose the right medications for patients.

Conditions

Diabetes

Cholesterol

Cancer

Blood Pressure Disorders

Heart Disease

Study ID

NCT06726590

Start date

Nov, 2025

Status verified date

Nov, 2024

Completion date

Nov, 2029

Anticipated

Primary completion date

Nov, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or
  • Individuals taking blood pressure or depression medications, even if less than five medications.
  • Ability to understand and give consent.
  • Able to consent to donate blood and/or urine samples and buccal swabs.
  • Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.
  • Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.
  • All genders.
  • Any age over 18 years.

Exclusion Criteria:

  • Individuals admitted to hospice.
  • Declines to participate or interact with staff/share their medical status.
  • A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,
  • Individuals who are unable or unwilling to provide consent.
  • Unable to verbally communicate and comprehend English language

Study Design

Enrollment

3000 participants

Anticipated

Interventions and Outcome Measures

Arms

Polypharmacy

Patients taking many medications or medications with severe side effects

Primary outcome measure

  • Frequency and nature of ADRs on the Naranjo Scale [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Kenneth S Ramos, MD, PhD

(713) 677-7440kramos@tamu.edu

Rick Silva, PhD

ricksilva@tamu.edu

Locations

Texas A&M Family Care

Recruiting

Bryan, Texas, United States, 77802

Contacts

Sara Rogers, PharmD

979.776.8440sararogers@tamu.edu

gneal@tamu.edu

Principal Investigator:

Kenneth S Kenneth S. Ramos, MD, PhD

More Information

Sponsor

Texas A&M University

Last update posted

Sep 12, 2025

Last verified

Nov, 2024

Keywords

  • REGISTRY
  • REPOSITORY
  • POLYPHARMACY
  • ADVERSE DRUG REACTION

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Texas A&M University on 2025-09-12.